Teijin Pharma receives approval for additional indication for XEOMIN in Japan

Bachem expands multi-site production capacities to meet rising demand

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland

Archish Fertility & IVF partners with Amaha Health for patient support and mental wellbeing

This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey

Biocon Biologics collaborates with National Cancer Society Malaysia

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First and only TROP2-directed therapy approved in the US for the treatment of lung cancer

Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH

WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy

Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1

Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume

Unichem receives Form 483 from USFDA with 3 observations for Roha API facility

The company will provide the necessary response to USFDA within stipulated 15 days

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month

Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia

BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population